Group 1 - The stock of Baiaosaitu-B (02315) increased nearly 10% during trading, reaching a new high of 39.46 HKD, and is currently up 7.86% at 38.72 HKD with a trading volume of 17.64 million HKD [1] - On January 9, Baiaosaitu announced a collaboration with Yushibo to establish an option and licensing agreement aimed at systematically evaluating the bispecific antibody-drug conjugate (BsADC) projects, thereby accelerating the development of the BsAD2C [1] - The agreement grants Yushibo an option for global exclusive licensing of two BsADC projects from Baiaosaitu, which will also receive an upfront payment, milestone payments, and revenue sharing upon exercise of the option [1] Group 2 - According to a recent report by Cinda Securities, Baiaosaitu's model animal sales and preclinical pharmacological evaluation businesses are experiencing rapid growth [2] - Baiaosaitu's business model is relatively unique compared to peers, focusing on high-margin humanized mouse strains and not offering low-margin standard strains, leading to high utilization of cage resources and the ability to expand internationally [2]
港股异动 盘中涨近10% 股价刷新上市新高 与育世博达成进一步合作